ClinicalTrials.gg
RecruitingNCT07527169Updated Nov 10, 2026

A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

A Phase 2 interventional study of Zanzalintinib in Metastatic Olfactory Neuroblastoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Esthesioneuroblastoma, Olfactory with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Esthesioneuroblastoma, Olfactory · United States.

Planned enrollment
32nd of 40
16 · median 34
Started
2026
the only one that year
Phase 2
12 of 60
2 open now
Registered
60th of 60
by date

Among the 60 studies in Esthesioneuroblastoma, Olfactory with a site in United States, this one is the 32nd largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2026, is one of 12 in phase 2, and was the 60th registered.

Esthesioneuroblastoma, Olfactory

75 studies on the registry are indexed under Esthesioneuroblastoma, Olfactory; 11 are open to participants now.

Browse Esthesioneuroblastoma, Olfactory studies →

Open to participants now

7 of the 60 studies in Esthesioneuroblastoma, Olfactory with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Esthesioneuroblastoma, Olfactory studies recruiting now, 5 (45%) set no upper age limit and 1 (9%) stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Esthesioneuroblastoma, Olfactory with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical research study is to learn if zanzalintinib can help to control recurrent/metastatic ONB. The safety of zanzalintinib will also be studied.

Read the detailed description

Primary Objectives:

  • To assess the efficacy of Zanzalintinib in patients with R/M ONB

Endpoint

ORR, defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) as measured by response evaluation criteria in solid tumors (RECIST), version 1.1, as determined by investigator radiologist assessment.

Secondary Objectives:

  • To assess the metabolic response of Zanzalintinib in patients with R/M ONB

Endpoint

Objective Metabolic Response Rate (OMRR), defined as the proportion of patients who achieve a complete metabolic response (CMR) or partial metabolic response (PMR), as measured by PERCIST v.1.0 using DOTATATE-PET imaging, based on investigator assessment by radiology and/or nuclear medicine.

  • To estimate the median duration of response (DOR)

Endpoint

DOR, defined as time from first documentation of CR or PR to the earliest date of documented disease progression or death from any cause, or last follow-up without disease progression or death, whichever occurs first.

  • Duration of metabolic response (DOMR)

Endpoint

DOMR, defined as time from first documentation of CMR or PMR to the earliest date of documented metabolic disease progression or death from any cause, or last follow-up without disease progression or death, whichever occurs first.

  • Time to response

Endpoint

Among objective responders (CR and PR), the time between the date treatment was started (C1D1) and first radiological evidence of CR or PR.

  • To estimate the median progression-free survival (PFS) and 12-months PFS rate

Endpoint

PFS, defined as the time from the date of dose initiation to the earliest date of documented disease progression, or death from any cause, or last follow-up without disease progression or death, whichever occurs first.

To estimate the median overall survival (OS) and 12-months OS

Endpoint

OS, defined as time from date of dose initiation to death from any cause or last follow-up without death.

  • To assess safety of Zanzalintinib

Endpoint

Safety will be measured as the incidence of adverse events (AEs) according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.

Tertiary/Exploratory Objectives

  • To explore biomarkers that may predict response to therapy

Endpoint

Correlation of clinical response with biomarkers at baseline and/or on treatment. Correlatives analysis may include, but are not limited to, genomic (tumor molecular profiling, RNAseq) and proteomics (mIF or IMC) profiling.

03

Conditions studied

  • Metastatic Olfactory Neuroblastoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must meet all the following inclusion criteria to be eligible for participation in this study:

  1. Subjects ≥18 years with histology-proven R/M ONB.
  2. Not amenable to curative intent surgery or radiotherapy
  3. per 1.1
  4. Performance status of 0 or 1
  5. VEGFR-inhibitor naïve (R/M ONB never treated with VEGFR inhibitors including Zanzalintinib)
  6. Adequate organ and marrow function, based upon meeting all the following laboratory criteria within 14 days before first dose of study treatment

    1. ≥ 9 g/dL without transfusion within 2 weeks prior to screening laboratory sample collection.
    2. ≥ 1500/mm3 (≥ 1.5 GI/L) without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection.
    3. ≥ 100 x 109/mL without transfusion within 2 weeks of screening laboratory sample collection.
  7. Laboratory measurements, renal function:

    1. ≥ 40 mL/min as assessed by the Cockcroft-Gault equation
    2. Urine protein creatinine ration (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol creatinine)
  8. Laboratory measurements, hepatic function:

    1. (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x . For subjects with documented bone ALP ≤ 5 x ULN.

      For subjects with CRPC and bone metastasis ALP ≤ 10 x ULN if predominantly bone-specific ALP.

    2. Total ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN ).
    3. (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.2 x upper limit of normal (ULN ).
  9. Sexually active fertile subjects and their partners must agree to use highly effective method of (defined in Appendix A) during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.

    a. Through 186 days after the last dose of zanzalintinib for women of (WOCBP) or through 96 days after the last dose of zanzalintinib for men

  10. Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes. In addition, females \< 55 years-of-age must have a serum follicle stimulating hormone [FSH] level > 40 mIU/mL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.
  11. Capable of understanding and complying with protocol requirement and must have signed .

Exclusion criteria

Exclusion Criteria:

All Patients

Patients who meet any of the following exclusion criteria are not eligible to be enrolled in this study:

  1. Prior radiation therapy for bone within 2 weeks and any other radiation therapy within 4 weeks, or systemic treatment with radionuclide within 6 weeks before first dose of study treatment; ongoing relevant complications from prior radiation therapy are not eligible.
  2. Active CNS disease (subjects with asymptomatic and stable, treated CNS lesions who have been off , radiation, or other CNS-directed therapy for at least 4 weeks are not considered active)
  3. Red blood cell transfusion dependence, defined as requiring more than 2 units of packed red blood cell transfusions during the 4-week period prior to screening. Red blood cell transfusions are permitted during the screening period and prior to enrollment to meet the inclusion criterion.
  4. Receipt of any type of small molecule kinase inhibitor (including Zanzalintinib) within 2 weeks before first dose of study treatment.
  5. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including ) within 4 weeks before first dose of study treatment.
  6. Current participation in another interventional clinical study
  7. Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin inhibitors) and inhibitors (eg, clopidogrel).

    Allowed anticoagulants are the following:

    1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).
    2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without hemorrhagic complications from the anticoagulation regimen.

    Note: Subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer.

  8. History of previous other than malignancy treated with curative intent within less than 5 years. Subjects with the following diagnoses represents an exception and may enroll if ≥ 1 year with no evidence of active disease before the first dose of the study drug.:

    1. Non-melanoma skin cancers with no current evidence of disease
    2. Melanoma in situ with no current evidence of disease
    3. Localized cancer of the prostate with prostate-specific antigen of \<1 ng/mL
    4. Treated or localized well-differentiated thyroid cancer
    5. Treated cervical carcinoma in situ
    6. Treated ductal/lobular carcinoma in situ of the breast
  9. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    1. Unstable of deteriorating cardiovascular disorders:

      • Congestive heart failure Class 3 or 4, class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes).
      • Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.
      • Stroke (including [TIA]), myocardial infarction, or other clinically significant arterial thrombotic and/or ischemic event within 6 months before first dose of study treatment.
      • Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before first dose of study treatment.

      Note: Subjects with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.

      Note: Subjects who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.

      • Prior history of myocarditis
      • interval calculated by the Fridericia formula (QTcF) > 480 ms within 14 days per (ECG) before first dose of study treatment.

      Note: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility.

    2. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation, and malabsorption syndrome.

      • Tumors invading the GI-tract from external viscera
      • Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis
      • Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before first dose unless cause of obstruction is definitively managed and subject is asymptomatic
      • Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.
      • Known gastric or esophageal varices
      • Ascites, pleural effusion, or pericardial fluid requiring drainage in last 4 weeks
      • Moderate to severe hepatic impairment ( B or C).
    3. Genitourinary bleeding: Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary haemorrhage) within 12 weeks before first dose of study treatment.
    4. Urine protein ≥ ++ or 24 h urine protein > 1.0 g as indicated by urinalysis. Requirement for haemodialysis or peritoneal dialysis.
    5. Symptomatic cavitating pulmonary lesions or endobronchial disease (asymptomatic or radiated lesions allowed)
    6. Lesions invading or encasing any major blood vessels
  10. Serious non-healing wound/ulcer/bone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.
  11. Presence of multiple factors affecting oral medications (such as inability to swallow, chronic diarrhea, and intestinal obstruction, which significantly affect drug administration and absorption);
  12. Female subjects who are pregnant or breast-feeding
  13. Known to any of the study drugs, the metabolites, or formulation
  14. Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.
  15. Major surgery (as defined in Appendix 1; eg, GI surgery, removal or of brain metastasis) within 8 weeks prior to first dose of study treatment. Prior laparoscopic surgeries (ie nephrectomy) within 4 weeks prior to first dose of study treatment. Minor surgery (eg, simple excision, tooth extraction) within 5 days before first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment.

    -Note: Fresh tumor biopsies should be performed at least 5 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.

  16. Other clinically significant disorders:

    1. active infections requiring systemic treatment (prophylactic antibiotics is allowed).
    2. Pharmacologically uncompensated, symptomatic hypothyroidism
    3. Pregnant or lactating females
    4. Known infection with acute or chronic or C, known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness except for subjects meeting all of the following criteria:

      • On stable retroviral therapy
      • CD4+ T cells > 200 per microliters
      • Undetectable viral load. Note: HIV testing will be performed at screening if and as is required by local regulation Note: To be eligible, participants taking CYP inhibitors (eg, zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose. Note: , and viral load are monitored per standard of care by the local health care provider.
  17. History of solid organ or stem cell transplant
  18. History of psychiatric illness likely to interfere with ability to comply with protocol requirement or give .
  19. Other conditions, which in the opinion of the investigator would compromise the safety of the patient or the patient's ability to comply with study
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Phase 2: Treatment with Zanzalintinib

    Participants will be enrolled into a single cohort (N=16). Enrolled participants will receive Zanzalintinib at a dose of 60 mg orally once daily in a 28-day cycle.

    Drug: Zanzalintinib

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Jul 2028, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
UT MD Anderson is now Recruiting
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    UT MD Anderson is now Recruiting
    + 3 other changes: identifiers, verification date and date precision
  2. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07527169
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Oct 1, 2026
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Luana Sousa, MD
Contact
lgsousa@mdanderson.org
713-628-5674
Luana Sousa, MD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion